J Korean Hip Soc 2008; 20(4): 305-310
Published online December 1, 2008
© The Korean Hip Society
이영균∙김기철∙최혜연∙장작∙구경회∙하용찬
서울대학교 의과대학 정형외과학교실
Correspondence to : 하용찬
경기도 성남시 분당구 구미로 166 서울대학교 의과대학 정형외과학교실
TEL: 82-31-787-7190
FAX: 82-31-787- 4056
E-mail: hychan@snubh.org
Purpose: Hip fractures in senile osteoporotic patients are associated with high rates of morbidity and mortality. Accordingly, it is important to prevent further fracture by treating the osteoporosis in these patients. In this study, we evaluated the complications and safety of intravenous bisphosphonate, which was injected shortly after the operation.
Materials and Methods: We prospectively studied the complications of administering intravenous bisphosphonate in 36 senile patients who were operated due to hip fracture between May 2008 and August 2008 at the authors’ hospital.
Results: Bisphosphonate was injected at a mean of 5 days (range, 2~11 days) after the operation for hip fracture. Fourteen patients (38.9%) experienced complications: pyrexia in 6, flu-like symptoms in 6, headache in 3, delirium in 3, myalgia in 2 and arthralgia in 2. However, no life-threatening complications were observed.
Conclusion: The incidence and severity of complications in our patients were comparable with those of the previous studies in patients who received intravenous bisphosphonate treatment weeks or months after the hip fracture operation. We recommend physicians be alert for patients to exhibit delirium in addition to the well-established post-infusion symptoms and to decide the correct time of infusion according to status of the patients after the operation.
Keywords Hip, Fracture, Osteoporosis, Intravenous bisphosphonate, Complication
J Korean Hip Soc 2008; 20(4): 305-310
Published online December 1, 2008 https://doi.org/10.5371/jkhs.2008.20.4.305
Copyright © The Korean Hip Society.
이영균∙김기철∙최혜연∙장작∙구경회∙하용찬
서울대학교 의과대학 정형외과학교실
Young-Kyun Lee, M.D., Ki-Choul Kim, M.D., Hye Yeon Choi, M.D., Jak Jang, M.D., Kyung-Hoi Koo, M.D., Yong-Chan Ha, M.D.
Department of Orthopedic Surgery, Seoul National University College of Medicine, Seoul, Korea
Correspondence to:하용찬
경기도 성남시 분당구 구미로 166 서울대학교 의과대학 정형외과학교실
TEL: 82-31-787-7190
FAX: 82-31-787- 4056
E-mail: hychan@snubh.org
Purpose: Hip fractures in senile osteoporotic patients are associated with high rates of morbidity and mortality. Accordingly, it is important to prevent further fracture by treating the osteoporosis in these patients. In this study, we evaluated the complications and safety of intravenous bisphosphonate, which was injected shortly after the operation.
Materials and Methods: We prospectively studied the complications of administering intravenous bisphosphonate in 36 senile patients who were operated due to hip fracture between May 2008 and August 2008 at the authors’ hospital.
Results: Bisphosphonate was injected at a mean of 5 days (range, 2~11 days) after the operation for hip fracture. Fourteen patients (38.9%) experienced complications: pyrexia in 6, flu-like symptoms in 6, headache in 3, delirium in 3, myalgia in 2 and arthralgia in 2. However, no life-threatening complications were observed.
Conclusion: The incidence and severity of complications in our patients were comparable with those of the previous studies in patients who received intravenous bisphosphonate treatment weeks or months after the hip fracture operation. We recommend physicians be alert for patients to exhibit delirium in addition to the well-established post-infusion symptoms and to decide the correct time of infusion according to status of the patients after the operation.
Keywords: Hip, Fracture, Osteoporosis, Intravenous bisphosphonate, Complication
Taek-Rim Yoon, M.D., Kyung-Soon Park, M.D.
J Korean Hip Soc 2008; 20(2): 80-90Taek Rim Yoon, MD, Kyung Soon Park, MD, Jae Young Moon, MD
J Korean Hip Soc 2011; 23(3): 184-191Ho Hyun Yun, MD, Ju-Won Yi, MD, Deuk-Soo Lim, MD, Sung Chul Park, MD, Seong Rok Oh, MD
J Korean Hip Soc 2011; 23(2): 142-150